mannitol has been researched along with Pseudomonas Infections in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (29.41) | 18.7374 |
| 1990's | 2 (11.76) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Abo Leyah, H; Aliberti, S; Chalmers, JD; De Soyza, A; Fardon, TC; Finch, S; Gao, YH; Lonergan, M; Tino, G | 1 |
| Cipolla, D; Lauretani, G; Lee, WH; Loo, CY; Ong, HX; Scalia, S; Traini, D; Young, P | 1 |
| Steinkamp, G | 1 |
| Hebert, WP; Mastoridis, P; O'Toole, GA; Orazi, G; Price, KE; Ruoff, KL | 1 |
| Britton, WJ; Carrigy, NB; Chan, HK; Finlay, WH; Gao, FG; Kutter, E; Leung, SS; Morales, S; Parumasivam, T; Vehring, R | 1 |
| Costabile, G; d'Angelo, I; d'Emmanuele di Villa Bianca, R; Del Porto, P; Imperi, F; Leoni, L; Miro, A; Mitidieri, E; Pompili, B; Quaglia, F; Sorrentino, R; Ungaro, F; Visca, P | 1 |
| Cavallaro, G; Craparo, EF; Cusimano, MG; Giammona, G; Porsio, B; Schillaci, D; Spigolon, D | 1 |
| Lin, Q; Shin, S; Tsifansky, MD; Yang, Y; Yeo, Y | 1 |
| Eissens, AC; Hinrichs, WL; Murugappan, S; Quax, WJ; van Merkerk, R; Visser, MR; Wahjudi, M | 1 |
| FINDER, RJ; HEWITT, CB; OVERHOLT, EL; PATTON, JF | 1 |
| Bailey, SH; Carter, EA; Ryan, CM; Schoenfeld, DA; Tompkins, RG | 1 |
| Khubchandani, KR; Oberley, RE; Snyder, JM | 1 |
| Riley, PS; Weaver, RE | 1 |
| Goto, S; Hasegawa, M; Kobayashi, I; Nishida, M | 1 |
| Chusid, MJ; Shea, ML | 1 |
| Shuck, JM | 1 |
| Gonzalez, EB | 1 |
1 review(s) available for mannitol and Pseudomonas Infections
| Article | Year |
|---|---|
[Dry powder inhalers in cystic fibrosis].
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Diuretics, Osmotic; Drug Compounding; Dry Powder Inhalers; Humans; Mannitol; Powders; Pseudomonas Infections; Tobramycin | 2014 |
1 trial(s) available for mannitol and Pseudomonas Infections
| Article | Year |
|---|---|
Relationship between Symptoms, Exacerbations, and Treatment Response in Bronchiectasis.
Topics: Administration, Inhalation; Bronchiectasis; Cohort Studies; Cough; Disease Progression; Dry Powder Inhalers; Forced Expiratory Volume; Hospitalization; Humans; Mannitol; Proportional Hazards Models; Pseudomonas Infections; Quality of Life; Scotland | 2020 |
15 other study(ies) available for mannitol and Pseudomonas Infections
| Article | Year |
|---|---|
Sweetening Inhaled Antibiotic Treatment for Eradication of Chronic Respiratory Biofilm Infection.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Cell Line, Tumor; Chronic Disease; Ciprofloxacin; Drug Combinations; Drug Resistance, Bacterial; Humans; Mannitol; Nebulizers and Vaporizers; Permeability; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 2018 |
Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
Topics: Biofilms; Cystic Fibrosis; Humans; Lung; Mannitol; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2015 |
Production of Inhalation Phage Powders Using Spray Freeze Drying and Spray Drying Techniques for Treatment of Respiratory Infections.
Topics: Administration, Inhalation; Aerosols; Freeze Drying; Leucine; Lung; Mannitol; Microbial Viability; Nebulizers and Vaporizers; Phage Therapy; Podoviridae; Powders; Pseudomonas; Pseudomonas Infections; Respiratory Tract Infections; Trehalose; Ultrasonics | 2016 |
Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Antifungal Agents; Candida albicans; Candidiasis; Drug Repositioning; Dry Powder Inhalers; Flucytosine; Humans; Hyaluronic Acid; Lung; Lung Diseases, Fungal; Male; Mannitol; Particle Size; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Rats, Wistar | 2016 |
Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
Topics: Anti-Bacterial Agents; Cell Line; Cystic Fibrosis; Drug Carriers; Drug Liberation; Epithelial Cells; Humans; Mannitol; Mucus; Nanocomposites; Polyelectrolytes; Polymers; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2017 |
Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.
Topics: Administration, Inhalation; Anti-Infective Agents; Ciprofloxacin; Cystic Fibrosis; Drug Carriers; Humans; Mannitol; Mucus; Pseudomonas aeruginosa; Pseudomonas Infections; Sodium Chloride | 2011 |
Development of a dry, stable and inhalable acyl-homoserine-lactone-acylase powder formulation for the treatment of pulmonary Pseudomonas aeruginosa infections.
Topics: Acyl-Butyrolactones; Administration, Inhalation; Amidohydrolases; Anti-Bacterial Agents; Bacterial Proteins; Drug Stability; Escherichia coli; Excipients; Inulin; Mannitol; Microscopy, Electron, Scanning; Powder Diffraction; Powders; Pseudomonas aeruginosa; Pseudomonas Infections; Trehalose; X-Ray Diffraction | 2013 |
GRAM-NEGATIVE SEPTICEMIA IN UROLOGY.
Topics: Anticoagulants; Colistin; Diagnosis; Drug Therapy; Enterobacter; Escherichia coli Infections; Heparin; Hydrocortisone; Kanamycin; Klebsiella; Mannitol; Proteus Infections; Pseudomonas Infections; Sepsis; Streptomycin; Urinary Tract Infections; Urology; Vasodilator Agents | 1965 |
Additive effects of thermal injury and infection on gut permeability.
Topics: Animals; Burns; Intestinal Absorption; Kidney; Male; Mannitol; Polyethylene Glycols; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Rats; Rats, Sprague-Dawley | 1994 |
Effects of surfactant protein A and NaCl concentration on the uptake of Pseudomonas aeruginosa by THP-1 cells.
Topics: Bacterial Capsules; Cystic Fibrosis; Dose-Response Relationship, Drug; Glycosaminoglycans; Humans; Lipopolysaccharides; Mannitol; Mannose; Monocytes; Osmolar Concentration; Phagocytosis; Pneumonia, Bacterial; Proteolipids; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Proteins; Pulmonary Surfactants; Saline Solution, Hypertonic; Sodium Chloride; Temperature | 2001 |
Recognition of Pseudomonas pickettii in the clinical laboratory: biochemical characterization of 62 strains.
Topics: Classification; Glucose; Humans; Mannitol; Nitrates; Oxidation-Reduction; Pseudomonas; Pseudomonas Infections | 1975 |
Co-existence of colonies with different serotypes and other biological characteristics in clinical isolates of Pseudomonas aeruginosa.
Topics: Gelatin; Humans; Maltose; Mannitol; Pseudomonas aeruginosa; Pseudomonas Infections; Serotyping; Urease; Xylose | 1992 |
Quantitation of corneal inflammation by chemiluminescense.
Topics: Animals; Cornea; Cryosurgery; Endotoxins; Escherichia coli; Guinea Pigs; Keratitis; Luminescent Measurements; Luminol; Mannitol; Neutrophils; Prednisolone; Pseudomonas aeruginosa; Pseudomonas Infections; Salicylates; Sodium Hydroxide; Tetradecanoylphorbol Acetate | 1986 |
Current practices in burn management.
Topics: Aged; Anuria; Bacterial Infections; Bandages; Burns; Child; Debridement; Digoxin; Hospital Units; Humans; Infusions, Parenteral; Male; Mannitol; Penicillins; Plasma; Postoperative Care; Pseudomonas Infections; Skin Transplantation; Sulfanilamides; Transplantation, Autologous; Transplantation, Homologous; Wound Infection | 1974 |
Control of infection after prostatectomy.
Topics: Bacteriuria; Cross Infection; Drainage; Humans; Male; Mannitol; Postoperative Care; Prostatectomy; Pseudomonas Infections; Surgical Wound Infection; Urea; Urinary Catheterization | 1966 |